iBio, Inc. Files 8-K Report

Ticker: IBIO · Form: 8-K · Filed: 2025-10-30T00:00:00.000Z

Sentiment: neutral

Topics: 8-K, filing, financials

TL;DR

iBio filed an 8-K, mostly financial docs and other events. No big news yet.

AI Summary

On October 30, 2025, iBio, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, along with other events and a Regulation FD disclosure. No specific financial figures or significant business events were detailed in the provided excerpt.

Why It Matters

This filing indicates that iBio, Inc. is providing updated information to the SEC, which could include important disclosures about the company's financial status or other material events.

Risk Assessment

Risk Level: low — The filing is a standard 8-K report, and the provided excerpt does not contain information that suggests immediate or significant risk.

Key Players & Entities

FAQ

What specific 'Other Events' are being disclosed by iBio, Inc. in this 8-K filing?

The provided excerpt does not detail the specific 'Other Events' being disclosed; it only lists 'Other Events' as an item information category.

What is the purpose of the 'Regulation FD Disclosure' mentioned in the filing?

The purpose of a Regulation FD Disclosure is to ensure that material non-public information is broadly disseminated to the public, preventing selective disclosure.

When was iBio, Inc. incorporated, and in which state?

iBio, Inc. was incorporated in Delaware, as indicated by the filing.

What is the principal executive office address for iBio, Inc.?

The principal executive offices are located at 11750 Sorrento Valley Road, Suite 200, San Diego, California 92121.

Does this 8-K filing contain any new financial statements or exhibits?

Yes, the filing lists 'Financial Statements and Exhibits' as an item information category, indicating that such documents are included.

From the Filing

0001420720-25-000033.txt : 20251030 0001420720-25-000033.hdr.sgml : 20251030 20251030072919 ACCESSION NUMBER: 0001420720-25-000033 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 18 CONFORMED PERIOD OF REPORT: 20251030 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20251030 DATE AS OF CHANGE: 20251030 FILER: COMPANY DATA: COMPANY CONFORMED NAME: iBio, Inc. CENTRAL INDEX KEY: 0001420720 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 262797813 STATE OF INCORPORATION: DE FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-35023 FILM NUMBER: 251432218 BUSINESS ADDRESS: STREET 1: 600 MADISON AVENUE, SUITE 1601 CITY: NEW YORK STATE: NY ZIP: 10022-1737 BUSINESS PHONE: 302 355-0650 MAIL ADDRESS: STREET 1: 600 MADISON AVENUE, SUITE 1601 CITY: NEW YORK STATE: NY ZIP: 10022-1737 FORMER COMPANY: FORMER CONFORMED NAME: iBioPharma, Inc. DATE OF NAME CHANGE: 20080806 FORMER COMPANY: FORMER CONFORMED NAME: InB:Biotechnologies, Inc. DATE OF NAME CHANGE: 20071210 8-K 1 ibio-20251030x8k.htm 8-K iBio, Inc._October 30, 2025 0001420720 false 0001420720 2025-10-30 2025-10-30 ​ ​ UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM  8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): October 30, 2025 iBio, Inc. (Exact name of registrant as specified in charter) Delaware (State or other jurisdiction of incorporation) ​ ​ 001-35023 26-2797813 (Commission File Number) (IRS Employer Identification No.) ​ 11750 Sorrento Valley Road , Suite 200 San Diego , California 92121 (Address of principal executive offices and zip code) ( 979 ) 446-0027 (Registrant’s telephone number including area code) N/A (Former Name and Former Address) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of registrant under any of the following provisions: ☐       Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐       Soliciting material pursuant to Rule 14a-12(b) under the Exchange Act (17 CFR 240.14a-12) ☐       Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐       Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: ​ ​ ​ Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $0.001 par value per share IBIO The Nasdaq Stock Market LLC ​ Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company   ☐ If an emerging growth company, indicate by checkmark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨ ​ ​ ​ ​ Item 7.01.       Regulation FD Disclosure.   On October 30, 2025, iBio, Inc. (the “Company”) issued a press release announcing new preclinical data from its obese non-human primate (NHP) study evaluating IBIO-610, potentially a first-in-class Activin E antibody candidate supported by preclinical data. The data will be presented by Cory Schwartz, Ph.D., Director of Research and Early Developmen

View on Read The Filing